Founders in digital health and founders in biotech tend to think of themselves as raising in different markets, from different investors, against different benchmarks. That has become less true every year since 2023, and 2026 is the year the overlap became impossible to ignore in the actual data.
Why the two markets are converging
Generalist and crossover funds, the large multi-stage vehicles that write checks across software, biotech and everything adjacent, allocate capital across healthcare broadly, not within a single vertical silo. When biotech capital markets tighten, as they have through several stretches of the last few years around clinical trial risk and a difficult public biotech market, some of that same generalist capital rotates toward digital health, where the underwriting question is commercial traction rather than clinical trial risk. When digital health cools, the reverse happens.
HSBC Innovation Banking's 2026 mid-year healthcare venture report is explicitly framed around helping investors "spot where capital is concentrating across" the healthcare venture landscape as a single system, not as separate biotech and digital health markets, which is itself evidence of how allocators are now thinking about the space.
The different risk profiles, and why that matters for pricing
The two categories carry genuinely different risk shapes, and that is precisely what makes them attractive as a portfolio pair to the same allocator:
| Dimension | Biotech | Digital health |
|---|---|---|
| Primary risk | Clinical and regulatory (does the drug work, does it get approved) | Commercial and adoption (does a health system or payer actually buy and keep using it) |
| Capital intensity | Very high, often binary outcomes at trial readouts | Lower per company, but requires sustained enterprise sales investment |
| Time to exit signal | Binary at each trial phase | More continuous, visible in renewal and expansion data |
| What a Series A funds | Preclinical to IND, or Phase 1 | Commercial proof points and initial enterprise contracts |
An allocator holding both categories is diversifying across risk types, not just across sub-sectors, which is exactly why the same LP base now funds both, and why the health of one category's public exit market affects sentiment and check size in the other, even though the underlying businesses have almost nothing in common operationally.
What this means concretely for a digital health founder
Your fundraising environment is affected by biotech's public market health, not just digital health's. A rough stretch for biotech IPOs or a string of failed Phase 3 readouts can tighten crossover fund enthusiasm for healthcare broadly, showing up as reduced digital health check sizes for reasons that have nothing to do with your company or your category's fundamentals.
Crossover investors bring biotech-style diligence discipline to digital health rounds, and founders should expect it. That means more rigorous evidence standards on clinical or outcomes claims than a pure software investor would apply, closer to what a biotech investor expects from a clinical data package.
The reverse is also becoming true. Biotech investors are increasingly comfortable underwriting the commercial and go-to-market risk of a digital health-adjacent diagnostics or therapeutics-enablement company, because they have spent the last several years watching digital health investors do exactly that kind of diligence.
The strategic implication for founders positioning a raise
If your company sits at the intersection, a diagnostics platform, a therapeutics-enablement tool, an AI drug discovery platform, you are now pitching directly into this combined capital pool, and you should build your data room to satisfy both underwriting traditions at once: commercial traction evidence for the digital health-minded reviewer, and rigorous, defensible clinical or scientific evidence for the biotech-minded reviewer on the same investment committee.
For a purely commercial digital health company with no clinical claims at all, the practical takeaway is different but related: understand which of your prospective investors are healthcare generalists managing a combined biotech and digital health book, because their appetite for your round can shift based on news in a category you do not operate in. Ask directly about a fund's current healthcare allocation split during your first conversation. It is a fair diligence question to ask an investor, and the answer tells you how exposed your term sheet timeline is to a category-wide event that has nothing to do with your company.
The takeaway
Digital health and biotech no longer raise in separate weather systems. The same generalist capital that prices a Phase 2 readout is pricing your Series C, and the correlation between the two categories' fortunes is now tight enough that it belongs in your fundraising planning, not just in a market commentary newsletter.
